AVCNF logo

AVCNF Avicanna Inc.

Other OTC · Drug Manufacturers - Specialty & Generic · Healthcare

$0.10
+0.00 (+3.23%)

Avicanna Inc. is a biopharmaceutical company already in its commercial phase, dedicated to the research and development of scientifically-backed products for global consumer health and pharmaceutical sectors. It maintains partnerships with Canadian academic and medical institutions. Its scientific approach, encompassing robust R&D and clinical development, underpins the commercialization of roughl…

Market Cap: $12.08Mwww.avicanna.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

80
80
Aug 14Aug 14

Quote

Day Range
$0.10 – $0.10
52-Week Range
$0.07 – $0.24
Volume
$109.0K
Market Cap
$12.08M
50-Day Avg
$0.09
200-Day Avg
$0.13
Prev Close
$0.09
Open
$0.10

Valuation & Ratios

P/E Ratio
-8.97
EPS
$-0.02
P/B Ratio
8.98
P/S Ratio
1.00
Debt/Equity
0.00
Current Ratio
0.86
Dividend Yield
+0.0%
Gross Margin
+50.4%

Returns & Efficiency

Return on Equity
-100.0%
Return on Assets
-13.4%
FCF Yield
-5.6%
EV/EBITDA
-12.80

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$25.46M$-2.84M$-0.02
2024$25.46M$-3.62M$-0.04
2023$16.79M$-8.74M$-0.10
2022$4.05M$-14.74M$-0.25
2021$3.27M$-16.77M$-0.41

Social Signal Score

30
5d
30
1 mentions
30d
30
1 mentions
60d
30
1 mentions
90d
30
1 mentions
news: 1

Earnings

Mon, Aug 17(tomorrow)

Consensus estimate $-0.03 per share

6of 6 quarters beat consensus

Typical surprise +83.4% (median, so one quarter with a near-zero estimate can't distort it)

  • Wed, May 13$-0.00 vs $-0.03beat
  • Mon, Nov 17$-0.01 vs $-0.02beat
  • Thu, Aug 14$-0.00 vs $-0.03beat
  • Wed, May 14$0.00 vs $-0.04beat
  • Wed, Nov 13$-0.01 vs $-0.03beat
  • Tue, Aug 13$-0.02 vs $-0.03beat

Estimates and results for AVCNF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

AVCNFhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsglobenewswire.com·19h ago·Negative

    Avicanna Reports Q2 2026 Financial Results Gross margin improves to 57%, supported by 48% quarterly growth in proprietary product sales QUIX™ rapid-onset portfolio prepared for Q3 launch with more than 35 commercial listings secured

    View source ↗